Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Deep-vein thrombosis: a United States cost model for a preventable and costly adverse event.

Mahan CE, Holdsworth MT, Welch SM, Borrego M, Spyropoulos AC.

Thromb Haemost. 2011 Sep;106(3):405-15. doi: 10.1160/TH11-02-0132.

PMID:
21833446
2.

The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs.

Grosse SD, Nelson RE, Nyarko KA, Richardson LC, Raskob GE.

Thromb Res. 2016 Jan;137:3-10. doi: 10.1016/j.thromres.2015.11.033. Review.

3.

Economic costs of diabetes in the U.S. In 2007.

American Diabetes Association..

Diabetes Care. 2008 Mar;31(3):596-615. doi: 10.2337/dc08-9017. Review. Erratum in: Diabetes Care. 2008 Jun;31(6):1271.

PMID:
18308683
5.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
6.

Economics of low-molecular weight heparins.

Rutschmann OT, Matchar DB.

Am J Manag Care. 2000 Nov;6(20 Suppl):S1054-65; quiz 1066-7. Review.

7.

The measurement and monitoring of surgical adverse events.

Bruce J, Russell EM, Mollison J, Krukowski ZH.

Health Technol Assess. 2001;5(22):1-194. Review.

8.

Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery.

Sullivan SD, Kahn SR, Davidson BL, Borris L, Bossuyt P, Raskob G.

Pharmacoeconomics. 2003;21(7):477-96. Review.

PMID:
12696988
9.

Economic considerations in the prevention and treatment of venous thromboembolism.

Hawkins D.

Am J Health Syst Pharm. 2004 Dec 1;61(23 Suppl 7):S18-21. Review.

PMID:
15597575
11.

The hidden risk of deep vein thrombosis--the need for risk factor assessment: case reviews.

Race TK, Collier PE.

Crit Care Nurs Q. 2007 Jul-Sep;30(3):245-54. Review.

PMID:
17579308
12.

[Direct and indirect diabetes costs in the world].

Logminiene Z, Norkus A, Valius L.

Medicina (Kaunas). 2004;40(1):16-26. Review. Lithuanian.

13.

Quality of life and economic costs associated with postthrombotic syndrome.

Kachroo S, Boyd D, Bookhart BK, LaMori J, Schein JR, Rosenberg DJ, Reynolds MW.

Am J Health Syst Pharm. 2012 Apr 1;69(7):567-72. doi: 10.2146/ajhp110241. Review.

PMID:
22441786
14.

Cost of illness studies for schizophrenia: components, benefits, results, and implications.

Genduso LA, Haley JC.

Am J Manag Care. 1997 Jun;3(6):873-7. Review.

Supplemental Content

Support Center